Clinical Effects of Activated Charcoal Unavailability on Treatment Outcomes for Oral Drug Poisoned Patients

Table 4

GCS and clinical outcomes compared between charcoal-available and charcoal-unavailable periods.

	Charcoal-available period				Charcoal-unavailable period	p-value^†
	Non-charcoal	Charcoal	Total	p-value
Aspiration pneumonia
GCS 13-15	7 (4.0%)	7 (7.4%)	14 (5.2%)	0.258	3 (2.1%)	0.119
GCS 9-12	7 (13.7%)	3 (10.7%)	10 (12.7%)	>0.990	4 (10.8%)	>0.999
GCS 3-8	14 (29.2%)	3 (15.8%)	17 (25.4%)	0.356	14 (36.8%)	0.216
Intubation
GCS 13-15	3 (1.7%)	6 (6.4%)	9 (3.4%)	0.071	3 (2.1%)	0.552
GCS 9-12	5 (9.8%)	4 (14.3%)	9 (11.4%)	0.713	3 (8.1%)	0.749
GCS 3-8	9 (18.8%)	8 (47.1%)	17 (25.4%)	0.064	10 (26.3%)	0.915
Vasopressor use
GCS 13-15	7 (4.0%)	3 (3.2%)	10 (3.7%)	>0.990	5 (3.4%)	0.868
GCS 9-12	4 (7.8%)	1 (3.6%)	5 (6.3%)	0.651	1 (2.7%)	0.663
GCS 3-8	6 (12.5%)	1 (5.3%)	7 (10.4%)	0.663	5 (13.2%)	0.753
Mortality
GCS 13-15	3 (1.7%)	1 (1.1%)	4 (1.5%)	>0.990	1 (0.7%)	0.660
GCS 9-12	1 (2.0%)	0 (0%)	1 (1.3%)	>0.990	1 (2.7%)	0.538
GCS 3-8	3 (6.3%)	0 (0%)	3 (4.5%)	0.553	0 (0%)	0.552
Hospital admission
GCS 13-15	50 (28.9%)	39 (41.5%)	89 (33.3%)	0.037	28 (19.2%)	0.002
GCS 9-12	26 (51.0%)	17 (60.7%)	43 (54.4%)	0.046	15 (40.5%)	0.163
GCS 3-8	36 (75.6%)	11 (57.9%)	47 (70.1%)	0.168	23 (60.5%)	0.315
ICU admission
GCS 13-15	2 (1.2%)	6 (6.4%)	8 (3.0%)	0.024	12 (8.2%)	0.028
GCS 9-12	3 (5.9%)	2 (7.1%)	5 (6.3%)	>0.990	6 (16.2%)	0.102
GCS 3-8	7 (14.6%)	4 (21.1%)	11 (16.4%)	0.492	12 (31.6%)	0.071
Number of patients
GCS 13-15	173	94	267		146
GCS 9-12	51	28	79		37
GCS 3-8	48	19	67		38

GCS: Glasgow Coma Scale; ICU: intensive care unit.
noncharcoal and charcoal.
^†Between charcoal-available and charcoal-unavailable periods.